US 5199942A
· Gillis et al.
· 1993
[cited by applicant]
US 5350674A
· Boenisch et al.
· 1994
[cited by applicant]
US 5359046A
· Capon
· 1994
[cited by examiner]
US 5585362A
· Wilson et al.
· 1996
[cited by applicant]
US 5686281A
· Roberts
· 1997
[cited by applicant]
US 7101550B2
· Wood et al.
· 2006
[cited by applicant]
US 7285522B2
· Van et al.
· 2007
[cited by applicant]
US 20060247191A1
· Finney et al.
· 2006
[cited by applicant]
US 20100316646A1
· Gao et al.
· 2010
[cited by applicant]
US 20110262457A1
· Weiner
· 2011
[cited by examiner]
CN 101355965
· 2009
[cited by applicant]
JP 2006518984
· 2006
[cited by applicant]
JP 6334398
· 2018
[cited by applicant]
WO 0129058A1
· 2001
[cited by applicant]
WO 0196584A2
· 2001
[cited by applicant]
WO 2004039840A1
· 2004
[cited by applicant]
WO 2005044996A2
· 2005
[cited by applicant]
WO 2010025177A1
· 2010
[cited by applicant]
WO 2011090762A1
· 2011
[cited by applicant]
Murphy et al. Induction by Antigen of Intrathymic Apoptosis of CD4+CD8+ TCRIo Thymocytes in Vivo (Science, 1990, 250:1720-1723) (Year: 1990).
[cited by examiner]
Zamoyska et al. Inability of CD8a' polypeptides to associate with p56kk correlates with impaired function in vitro and lack of expression in vivo (Nature, 1989, 342:278-281) (Year: 1989).
[cited by examiner]
Bauer et al. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7 (Scand J Immuno, 1995, 42:317-323) (Year: 1995).
[cited by examiner]
European Patent Application No. 19162250.5—Extended European Search Report dated Sep. 5, 2019.
[cited by applicant]
Japanese Patent Application No. 2018-084610—Notice of Reasons for Rejection dispatched Oct. 30, 2019.
[cited by applicant]
Watanabe , et al., “BTLA is a lymphocyte inhibitory receptor with similariities to CTLA-4 and PD-1.”, 2003, Nature Immunology 4(7):670-679.
[cited by applicant]
Barrett David M et al, “Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells”, 101st Annual Meeting of the American-Association-For-Cancer-Re…
[cited by applicant]
Japanese Patent Application No. 2018-084610—Notice of Reasons for Rejection dispatched Mar. 27, 2019.
[cited by applicant]
Australian Patent Application No. 2015590342—Examination Report No. 1, issued Jun. 30, 2016.
[cited by applicant]
Chinese Patent Application No. 201280041432.6—Fifth Office Action dated May 14, 2018.
[cited by applicant]
Chinese Patent Application No. 201280041432.6—Office Action issued Dec. 31, 2015.
[cited by applicant]
Chinese Patent Application No. 201280041432.6—Third Office Action issued Jan. 19, 2017.
[cited by applicant]
Chinese Patent Application No. 2012800414326—Decision of Rejection dated Oct. 24, 2018.
[cited by applicant]
Chinese Patent Application No. 2012800414326—Office Action dated Oct. 9, 2017.
[cited by applicant]
Colombia Patent Application No. 14-12252—Office Action issued May 10, 2016 (no available translation).
[cited by applicant]
Colombia Patent Application No. 14-12252—Office Action issued Sep. 2015 (no available translation).
[cited by applicant]
Eurasian Region Patent Application No. 201490364/28—Office Action issued Jan. 2016.
[cited by applicant]
European Patent Application No. 12820516.8—Office Action issued Jul. 14, 2016.
[cited by applicant]
European Patent Application No. 12820516.8—Official Communication pursuant to Article 94(3) EPC dated Sep. 14, 2017.
[cited by applicant]
European Search Report for European Patent Application No. 12820516.8 dated Mar. 30, 2015.
[cited by applicant]
International search report for PCT/US12/48543 dated Oct. 16, 2012.
[cited by applicant]
Japanese Patent Application No. 2014-523064—Notice of Reasons for Rejection issued May 23, 2016.
[cited by applicant]
Japanese Patent Application No. 2014-523064—Office Action dated May 11, 2017.
[cited by applicant]
Singapore Patent Application No. 2014004170—Written Opinion issued May 23, 2016.
[cited by applicant]
Chinese Patent Application No. 201280041432.6—Second Office Action issued Jul. 19, 2016. ,2016.
[cited by applicant]
Beck, et al.,Enterocolitis in Patients with Cancer after Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4, 2006, J Clin Oncol 24:2283-9.
[cited by applicant]
Bierer, et al.,Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology, Curr. Opin. Immun. 5:763-773, 1993.
[cited by applicant]
Bird, et al.,Single-chain antigen-binding proteins, 1988, Science 242:423-426.
[cited by applicant]
Blansfield, et al.,Cytotoxic T-Lymphocyte-Associated antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients with Metastatic Melanoma and Renal Cancer, 2005, J Immunother 28:593-8.
[cited by applicant]
Carpenito, et al.,Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, 2009, PNAS 106(9):3360-3365.
[cited by applicant]
Cheever, et al.,Twelve immunotherapy drugs that could cure cancers, 2008, Immunol Rev 222:357-68 (Abstract).
[cited by applicant]
Chemnitz, et al.,B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells that can be Initiated by Multiple Phosphotyrosine Motifs., 2006, J Immunol 176…
[cited by applicant]
Dennehy, et al.,Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses, 2006, J Immunol 176:5725-5729.
[cited by applicant]
Derré, et al.,BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination, 2010, J Clin Invest 120:157-67.
[cited by applicant]
Dougan, et al.,Immune therapy for cancer, 2009, Annual Review of Immunology 27:83-117 (Abstract).
[cited by applicant]
Finney, et al.,Activation of Resting Human Primary T cells with Chimeric Receptors: Costimulation from CD28, Indcible Costimulatory, CD134 and CD137 in Series with Signals from the TCRz Chain, J Immunol 2004, 174:104-11…
[cited by applicant]
Garaude, et al.,ICOStomizing immunotherapies with T(H)17, 2010, Sci Transl Med 2(55):55ps2 (Abstract).
[cited by applicant]
Henderson, et al.,“Comparison of the effects of FK-506, cyclosporine A and rapamycin on IL-2 production.”, Immun. 73:316-321, 1991.
[cited by applicant]
Huston, et al.,“Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
June, et al.,Engineering lymphocyte subsets: tools, trials and tribulations, Nat Rev Immunol 9:704, 2009.
[cited by applicant]
Lajaunias, et al.,Constitutive repressor activity of CD33 on human moncytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling., Eur J Immunol. 2005, 35:243-251.
[cited by applicant]
Laport, et al.,Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation, 2003, Blood 102:2004-…
[cited by applicant]
Levine, et al.,Gene transfer in humans using a conditionally replicating lentiviral vector, 2006, Proc Natl Acad Sci U S A 103:17372-17377.
[cited by applicant]
Liu, et al.,Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes, Cell 66:807-815, 1991.
[cited by applicant]
Martin-Orozco, et al.,Th17 cells promote cytotoxic T cell activation in tumor immunity, 2009, Immunity 31:787-98.
[cited by applicant]
Moon, et al., May 2014, 17th Annual Meeting of the American Society of Gene and Cell Therapy “APD1-CD28 “Switch Receptor” Is able to augment Mesothelin-Directed Chimeric Antigen Receptor T Cell Therapy in a Resistant In…
[cited by applicant]
Mumtaz, et al.,Design of liposomes for circumventing the reticuloendothelial cells, 1991 Glycobiology 5: 505-10.
[cited by applicant]
Parry, et al.,CTLA-4 and PD-1 Recptors Inhibit T-cell Activation by Distinct Mechanisms, Mol Cell Biol. Nov. 2005;25(21):9543-9553.
[cited by applicant]
Paulos, et al.,Putting the brakes on BTLA in T cell-mediated cancer immunotherapy, 2010 J Clin Invest 120 (1):76-80.
[cited by applicant]
Paulos, et al.,The inducible costimulatory (ICOS) is critical for the development of human T(H)17 cells, 2010, Science Translational Medicine 2:55-78 (Abstract).
[cited by applicant]
Prosser, et al.,Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1: CD28 chimeric receptor, 2012, Molecular Immunology 51(3):263-272 (Abstract).
[cited by applicant]
Riley, et al.,The CD28 family: a T-cell reheostat for therapeutic control of T-cell activation, 2005, Blood 105:13-21.
[cited by applicant]
Ryo, et al.,Regulation of immune response by T cell co-signaling, Japanese Journal of Clinical Immunology, 2005, vol. 28, No. 1, pp. 21-32 (with partial English translation).
[cited by applicant]
Schroers, et al.,Gene transfer into human T lymphocytes and natural killer cells by AD5/F35 chimeric adenoviral vectors, Exp Hematol 32:536, 2004 (Abstract).
[cited by applicant]
Ui-Tei, et al.,Sensitive assay of RNA interference in
[cited by applicant]
Wherry, et al.,T Cell Exhaustion, Nature Immunology ,2011 ,492-498.
[cited by applicant]
Yin, et al.,Short cytoplasmic SDYMNM segment of CD28 is sufficient to convert CTLA-4 to a positive signaling receptor., 2003, Journal of Leukocyte Biology 73:178-182.
[cited by applicant]
Zhao, et al.,Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res 70:9062, 2010.
[cited by applicant]
Berry, L. J. et al., “Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells,” Tissue Antigens (2009) 74: 277-289.
[cited by applicant]
Bochner, B., “Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors,” Clin. Exp. Allergy (2009), 39(3): 317-324.
[cited by applicant]
Boyington J. et al., “Structure of CD94 reveals a novel C-type lectin fold: Implications for the NK cell-associated CD94/NKG2 receptors,” Immunity (1999), 10: 75-82.
[cited by applicant]
Carter L. et al., “PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2,” Eur. J. Immunol. (2002), 32: 634-643.
[cited by applicant]
Chang, C. et al., “Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily,” Eur. J. Immunol. (1995), 25: 2433-2437.
[cited by applicant]
Chou, K. and Elrod D., Prediction of membrane protein types and subcellular locations, Proteins: Structure, Function and Genetics, (1999), 34: 137-153.
[cited by applicant]
Davis D. and Maher J., “Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells,” Arch. Immunol. Ther. Exp. (2010), 58: 165-178.
[cited by applicant]
Kellar, D. et al., “CD56-Specific T Cells Can Distinguish between Allogeneic and Autologous CD56+ Targets,” Abstract 500, Molecular Therapy (May 2011 ), 19, Supplement 1: S192-S193.
[cited by applicant]
Li, Z. et al. , “Paradoxical roles of IL-4 in tumor immunity,” Cellular & Molecular Immunology (2009), 6(6): 415-422.
[cited by applicant]
Liu, X. et al., “A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors,” Cancer Res. (2016), 76(6): 1578-1590.
[cited by applicant]
Ngo, M. et al., “Ex vivo gene transfer for improved adoptive immunotherapy of cancer,” Human Molecular Genetics (Mar. 17, 2011 ), 20(1 ):R93-R99.
[cited by applicant]
Olver, S. et al., “The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?,” Tissue Antigens (2007), 69: 293-298.
[cited by applicant]
Prosser, M. et al., “Mechanistic Studies of PD-1 Signaling in the Conversion of Effector T Cells to Functional Exhaustion,” Abstract 565, Molecular Therapy (2009), 17, Supplement 1: S216.
[cited by applicant]
Prosser, M. et al., “Primary Human cos+ T Cells Engineered To Express a PD1-CD28 Chimeric Receptor Are Co-Stimulated through the Exploitation of Tumor Expressed PD-L 1,” Abstract 49, Molecular Therapy (May 2011 ), 19, S…
[cited by applicant]
Prosser, M. et al.,Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1: CD28 chimeric receptor, 2012, Molecular Immunology 51(3):263-272.
[cited by applicant]
Prosser, M., “Development of Genetic Engineering Platforms to Protect T Cells Against Functional Exhaustion, Dissertation from 2011: Development of Genetic Engineering Platforms to Protect T Cells Against Functional Exh…
[cited by applicant]
Ramos C. and Dotti G., “Chimeric Antigen Receptor (CAR)-Engineered Lymphocytes for Cancer Therapy,” Expert Opinion on Biological Therapy (Apr. 4, 2011) 11(7): 855-873.
[cited by applicant]
Riley J. and June C., “The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation,” Blood (2005), 105 (1): 13-21.
[cited by applicant]
Sadelain, M., “T-cell engineering for cancer immunotherapy,” The Cancer Journal (2009), 15(6): 451-455.
[cited by applicant]
Wilkie, S. et al., “Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4,” J Biol Chem. Aug. 13, 2010;285(33):25538-44.
[cited by applicant]